Lion Point Capital LP Acquires 40,000 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Lion Point Capital LP boosted its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 1.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,340,207 shares of the company’s stock after purchasing an additional 40,000 shares during the period. Milestone Pharmaceuticals makes up approximately 5.6% of Lion Point Capital LP’s holdings, making the stock its 3rd biggest position. Lion Point Capital LP owned about 4.39% of Milestone Pharmaceuticals worth $3,089,000 as of its most recent SEC filing.

Separately, BNP Paribas Financial Markets boosted its position in shares of Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after buying an additional 10,800 shares during the period. 86.18% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on MIST shares. Rodman & Renshaw began coverage on Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They set a “buy” rating and a $9.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd.

Milestone Pharmaceuticals Price Performance

NASDAQ MIST opened at $1.52 on Friday. Milestone Pharmaceuticals Inc. has a fifty-two week low of $1.12 and a fifty-two week high of $3.52. The stock’s 50-day moving average is $1.45 and its two-hundred day moving average is $1.54. The firm has a market cap of $80.97 million, a P/E ratio of -1.22 and a beta of 1.71. The company has a debt-to-equity ratio of 1.61, a current ratio of 19.13 and a quick ratio of 19.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. On average, analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.71 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.